These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

580 related items for PubMed ID: 27357813

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. A US Registry-Based Assessment of Use and Impact of Chemotherapy in Stage I HER2-Positive Breast Cancer.
    Parsons BM, Uprety D, Smith AL, Borgert AJ, Dietrich LL.
    J Natl Compr Canc Netw; 2018 Nov; 16(11):1311-1320. PubMed ID: 30442732
    [Abstract] [Full Text] [Related]

  • 3. Distant invasive breast cancer recurrence risk in human epidermal growth factor receptor 2-positive T1a and T1b node-negative localized breast cancer diagnosed from 2000 to 2006: a cohort from an integrated health care delivery system.
    Fehrenbacher L, Capra AM, Quesenberry CP, Fulton R, Shiraz P, Habel LA.
    J Clin Oncol; 2014 Jul 10; 32(20):2151-8. PubMed ID: 24888815
    [Abstract] [Full Text] [Related]

  • 4. Effects of trastuzumab on locoregional recurrence in human epidermal growth factor receptor 2-overexpressing breast cancer patients treated with chemotherapy and radiotherapy.
    Jeon SH, Shin KH, Kim JH, Kim K, Kim IA, Lee KH, Kim TY, Im SA.
    Breast Cancer Res Treat; 2018 Dec 10; 172(3):619-626. PubMed ID: 30209731
    [Abstract] [Full Text] [Related]

  • 5. Long-Term Survival Analysis of Adjuvant Chemotherapy with or without Trastuzumab in Patients with T1, Node-Negative HER2-Positive Breast Cancer.
    He X, Ji J, Tian M, Esteva FJ, Hortobagyi GN, Yeung SJ.
    Clin Cancer Res; 2019 Dec 15; 25(24):7388-7395. PubMed ID: 31515457
    [Abstract] [Full Text] [Related]

  • 6. Benefit of adjuvant chemotherapy with or without trastuzumab in pT1ab node-negative human epidermal growth factor receptor 2-positive breast carcinomas: results of a national multi-institutional study.
    de Nonneville A, Gonçalves A, Zemmour C, Classe JM, Cohen M, Lambaudie E, Reyal F, Scherer C, Muracciole X, Colombo PE, Giard S, Rouzier R, Villet R, Chopin N, Darai E, Garbay JR, Gimbergues P, Sabiani L, Coutant C, Sabatier R, Bertucci F, Boher JM, Houvenaeghel G.
    Breast Cancer Res Treat; 2017 Apr 15; 162(2):307-316. PubMed ID: 28155054
    [Abstract] [Full Text] [Related]

  • 7. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J, Kanomata N, Yamashita T, Shimo T, Mizutoh A, Moriya T, Sonoo H.
    Breast Cancer; 2015 May 15; 22(3):292-9. PubMed ID: 23749689
    [Abstract] [Full Text] [Related]

  • 8. Survival analysis based on human epidermal growth factor 2 status in stage II-III gastric cancer.
    Cho JH, Lim JY, Cho JY.
    World J Gastroenterol; 2017 Nov 07; 23(41):7407-7414. PubMed ID: 29151694
    [Abstract] [Full Text] [Related]

  • 9. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial.
    Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, de Azambuja E, Castro G, Untch M, Smith I, Gianni L, Baselga J, Al-Sakaff N, Lauer S, McFadden E, Leyland-Jones B, Bell R, Dowsett M, Jackisch C, Herceptin Adjuvant (HERA) Trial Study Team.
    Lancet; 2017 Mar 25; 389(10075):1195-1205. PubMed ID: 28215665
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of adjuvant trastuzumab in women with HER2-positive T1a or bN0M0 breast cancer: a population-based cohort study.
    Ali S, Hendry J, Le D, Mondal PK, Sami A, Chalchal H, Haider K, Ahmed O, El-Gayed A, Wright P, Pauls M, Johnson K, Ahmed S.
    Sci Rep; 2022 Jan 20; 12(1):1068. PubMed ID: 35058536
    [Abstract] [Full Text] [Related]

  • 11. Predictive factors of pathologic complete response of HER2-positive breast cancer after preoperative chemotherapy with trastuzumab: development of a specific predictor and study of its utilities using decision curve analysis.
    Jankowski C, Guiu S, Cortet M, Charon-Barra C, Desmoulins I, Lorgis V, Arnould L, Fumoleau P, Coudert B, Rouzier R, Coutant C, Reyal F.
    Breast Cancer Res Treat; 2017 Jan 20; 161(1):73-81. PubMed ID: 27807808
    [Abstract] [Full Text] [Related]

  • 12. A population-based recurrence risk management study of patients with pT1 node-negative HER2+ breast cancer: a National Clinical Database study.
    Kubo M, Kawai M, Kumamaru H, Miyata H, Tamura K, Yoshida M, Ogo E, Nagahashi M, Asaga S, Kojima Y, Kadoya T, Aogi K, Niikura N, Miyashita M, Iijima K, Hayashi N, Yamamoto Y, Imoto S, Jinno H.
    Breast Cancer Res Treat; 2019 Dec 20; 178(3):647-656. PubMed ID: 31451979
    [Abstract] [Full Text] [Related]

  • 13. Adjuvant Chemotherapy and Trastuzumab Is Safe and Effective in Older Women With Small, Node-Negative, HER2-Positive Early-Stage Breast Cancer.
    Cadoo KA, Morris PG, Cowell EP, Patil S, Hudis CA, McArthur HL.
    Clin Breast Cancer; 2016 Dec 20; 16(6):487-493. PubMed ID: 27622751
    [Abstract] [Full Text] [Related]

  • 14. The impact of ERBB-family germline single nucleotide polymorphisms on survival response to adjuvant trastuzumab treatment in HER2-positive breast cancer.
    Toomey S, Madden SF, Furney SJ, Fan Y, McCormack M, Stapleton C, Cremona M, Cavalleri GL, Milewska M, Elster N, Carr A, Fay J, Kay EW, Kennedy S, Crown J, Gallagher WM, Hennessy BT, Eustace AJ.
    Oncotarget; 2016 Nov 15; 7(46):75518-75525. PubMed ID: 27776352
    [Abstract] [Full Text] [Related]

  • 15. Benefit of adjuvant chemotherapy and trastuzumab in patients with HER2-positive, node-negative breast tumors ≤ 10 mm: a nationwide study.
    Hassing CMS, Mejdahl MK, Lænkholm AV, Kroman N, Knoop AS, Tvedskov THF.
    Breast Cancer Res Treat; 2022 Nov 15; 196(1):197-206. PubMed ID: 36076126
    [Abstract] [Full Text] [Related]

  • 16. Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study.
    Vaz-Luis I, Ottesen RA, Hughes ME, Mamet R, Burstein HJ, Edge SB, Gonzalez-Angulo AM, Moy B, Rugo HS, Theriault RL, Weeks JC, Winer EP, Lin NU.
    J Clin Oncol; 2014 Jul 10; 32(20):2142-50. PubMed ID: 24888816
    [Abstract] [Full Text] [Related]

  • 17. Endocrine sensitivity is decisive for patient outcome in small node-negative breast cancers (BC) (pT1a,b) - results from the Munich Cancer Registry.
    Kolben T, Harbeck N, Wuerstlein R, Schubert-Fritschle G, Bauerfeind I, Schrodi S, Engel J.
    Breast; 2015 Feb 10; 24(1):24-31. PubMed ID: 25543874
    [Abstract] [Full Text] [Related]

  • 18. T1N0 triple negative breast cancer: risk of recurrence and adjuvant chemotherapy.
    Kaplan HG, Malmgren JA, Atwood M.
    Breast J; 2009 Feb 10; 15(5):454-60. PubMed ID: 19671105
    [Abstract] [Full Text] [Related]

  • 19. Effectiveness of neo-adjuvant systemic therapy with trastuzumab for basal HER2 type breast cancer: results from retrospective cohort study of Japan Breast Cancer Research Group (JBCRG)-C03.
    Sagara Y, Takada M, Ohi Y, Ohtani S, Kurozumi S, Inoue K, Kosaka Y, Hattori M, Yamashita T, Takao S, Sato N, Iwata H, Kurosumi M, Toi M.
    Breast Cancer Res Treat; 2018 Oct 10; 171(3):675-683. PubMed ID: 29971625
    [Abstract] [Full Text] [Related]

  • 20. Long-term cardiovascular outcomes and overall survival of early-stage breast cancer patients with early discontinuation of trastuzumab: a population-based study.
    Gong IY, Verma S, Yan AT, Ko DT, Earle CC, Tomlinson GA, Trudeau ME, Krahn MD, Krzyzanowska MK, Brezden-Masley CB, Gavura S, Peacock S, Chan KK.
    Breast Cancer Res Treat; 2016 Jun 10; 157(3):535-44. PubMed ID: 27271767
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.